Cabaletta Bio
CABA-201(Cabaletta Bio)은 Pemphigus Vulgaris 표적 세포·유전자 치료로, Relapsing Multiple Sclerosis (RMS); Progressive Multiple Sclerosis (PMS) 영역에서 개발·상용화 중입니다. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 6건의 관련 임상이 등록되어 있습니다. 차별점: Novel examination of CABA-201 generated from primary T cells from multiple patients with autoimmune disease displayed ro.
Pemphigus Vulgaris
Relapsing Multiple Sclerosis (RMS); Progressive Multiple Sclerosis (PMS)
Recruiting
CAR T therapy in a subject with immune-mediate necrotizing myopat
Novel examination of CABA-201 generated from primary T cells from multiple patients with autoimmune disease displayed ro
immune-mediated inflammatory disorders of skeletal muscles with non-muscle involvement in some people, which carry significant morbidit
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Cabaletta Bio
CABA-201(Cabaletta Bio)은 Pemphigus Vulgaris 표적 세포·유전자 치료로, Relapsing Multiple Sclerosis (RMS); Progressive Multiple Sclerosis (PMS) 영역에서 개발·상용화 중입니다. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 6건의 관련 임상이 등록되어 있습니다. 차별점: Novel examination of CABA-201 generated from primary T cells from multiple patients with autoimmune disease displayed ro.
Pemphigus Vulgaris
Relapsing Multiple Sclerosis (RMS); Progressive Multiple Sclerosis (PMS)
Recruiting
CAR T therapy in a subject with immune-mediate necrotizing myopat
Novel examination of CABA-201 generated from primary T cells from multiple patients with autoimmune disease displayed ro
immune-mediated inflammatory disorders of skeletal muscles with non-muscle involvement in some people, which carry significant morbidit
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.